Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cantargia AB ( (SE:CANTA) ).
Cantargia AB announced the release of its interim report for the first nine months of 2025, scheduled for November 19, 2025. The company will hold an audiocast and teleconference on the same day to present the report and engage with investors, analysts, and media. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction following the recent acquisition of CAN10 by Otsuka Pharmaceutical.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Their primary oncology program, nadunolimab (CAN04), is being clinically studied in combination with chemotherapy for cancers such as pancreatic, non-small cell lung, and triple-negative breast cancer. Cantargia also has a second development program, CAN10, targeting autoimmune and inflammatory diseases.
Average Trading Volume: 2,667,628
Technical Sentiment Signal: Buy
Current Market Cap: SEK815.4M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.